KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (ONC) Enterprise Value (2016 - 2025)

BeOne Medicines (ONC) has disclosed Enterprise Value for 11 consecutive years, with -$2.5 billion as the latest value for Q1 2025.

  • On a quarterly basis, Enterprise Value rose 9.91% to -$2.5 billion in Q1 2025 year-over-year; TTM through Mar 2025 was -$2.5 billion, a 9.91% increase, with the full-year FY2024 number at -$2.6 billion, up 17.23% from a year prior.
  • Enterprise Value was -$2.5 billion for Q1 2025 at BeOne Medicines, up from -$2.6 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$9.3 million in Q3 2024 to a low of -$5.7 billion in Q2 2022.
  • A 5-year average of -$2.9 billion and a median of -$2.8 billion in 2024 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: tumbled 263.95% in 2023, then skyrocketed 99.71% in 2024.
  • BeOne Medicines' Enterprise Value stood at -$2.2 billion in 2021, then crashed by 102.24% to -$4.5 billion in 2022, then rose by 30.0% to -$3.2 billion in 2023, then increased by 17.23% to -$2.6 billion in 2024, then rose by 4.22% to -$2.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Enterprise Value are -$2.5 billion (Q1 2025), -$2.6 billion (Q4 2024), and -$9.3 million (Q3 2024).